Table 1

Revertant formation of HSV1(17+) UL36 mutantsa

HSV1 strain titratedTiter (PFU/ml [103])Ratio of mutant to revertant plaques
Vero-HS30Verob
HSV1(17+)blueLoxNDc400,000ND
HSV1(17+)blueLox ΔUL3612,000<1>12,000:1
HSV1(17+)blueLox-UL36codon2211stop33,000142,357:1
HSV1(17+)blueLox-UL36codon2430stop29,00093,222:1
HSV1(17+)blueLox-UL36codon2894stop19,000<1>19,000:1
HSV1(17+)blueLox-UL36codon2998stop29,000<1>29,000:1
  • a Preparations of HSV1 UL36 mutants were titrated in triplicate on the complementing cell line Vero-HS30 and also on the noncomplementing parental Vero cells to determine the amount of revertants in parallel. For comparison, the parental HSV1(17+)blueLox strain from a parallel preparation was also titrated.

  • b The input virus caused severe cytopathic effects at higher concentrations.

  • c ND, not determined.